| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
45,285 |
40,905 |
$3.32M |
| T1015 |
Clinic visit/encounter, all-inclusive |
12,363 |
11,311 |
$1.39M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,757 |
13,346 |
$1.26M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,786 |
3,451 |
$204K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,148 |
6,918 |
$101K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,546 |
1,862 |
$54K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,813 |
2,451 |
$52K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
287 |
277 |
$38K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
794 |
748 |
$29K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
734 |
679 |
$26K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
363 |
341 |
$19K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
80 |
80 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
96 |
88 |
$8K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
145 |
135 |
$5K |
| 81003 |
|
1,425 |
1,315 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,616 |
1,458 |
$2K |
| 99051 |
|
72 |
69 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,038 |
1,803 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
38 |
37 |
$851.01 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
22 |
19 |
$716.84 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
13 |
13 |
$602.41 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
292 |
254 |
$476.31 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
34 |
27 |
$357.70 |
| 81025 |
|
31 |
29 |
$246.40 |
| 71046 |
Radiologic examination, chest; 2 views |
15 |
12 |
$243.06 |
| A6446 |
Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard |
573 |
539 |
$178.84 |
| 36415 |
Collection of venous blood by venipuncture |
39 |
38 |
$85.80 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
13 |
13 |
$55.75 |
| A4928 |
Surgical mask, per 20 |
37 |
35 |
$14.50 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
18 |
12 |
$11.22 |
| 00000 |
|
90 |
88 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,186 |
1,057 |
$0.00 |